2010
DOI: 10.1179/1743288x10y.0000000004
|View full text |Cite
|
Sign up to set email alerts
|

Use of pedometers and accelerometers in clinical populations: validity and reliability issues

Abstract: Background: Pedometers and accelerometers are often used in clinical research studies, and have the potential to provide valid and objective information on physical activity. Objectives: The purposes of this review are to introduce clinicians to various activity monitors that are commercially available, and to discuss their strengths and limitations. Scientific articles over the past 20 years were reviewed, and the most common types of physical activity monitors were identified. Emphasis was placed on devices … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
92
0
3

Year Published

2013
2013
2021
2021

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 113 publications
(95 citation statements)
references
References 51 publications
0
92
0
3
Order By: Relevance
“…Therefore, participants were inadvertently exposed to some PA intervention with the Fitbit One during baseline measure of PA and prior to the start of the study, which could have diminished the effects of either the Fitbit One and/or text messaging. A strength of this study was the use of the Actigraph GT3X + , which is a valid and reliable measure of PA. 46,47 A validation study has compared Fitbit One measures with the Actigraph GT3X+ for steps that were taken on a treadmill, 51 and validation in a real-world setting is currently underway. More generally, improvements are needed in these technologies for more accurate measures across an array of activities beyond steps (e.g., cycling and swimming).…”
Section: Study Limitationsmentioning
confidence: 99%
See 1 more Smart Citation
“…Therefore, participants were inadvertently exposed to some PA intervention with the Fitbit One during baseline measure of PA and prior to the start of the study, which could have diminished the effects of either the Fitbit One and/or text messaging. A strength of this study was the use of the Actigraph GT3X + , which is a valid and reliable measure of PA. 46,47 A validation study has compared Fitbit One measures with the Actigraph GT3X+ for steps that were taken on a treadmill, 51 and validation in a real-world setting is currently underway. More generally, improvements are needed in these technologies for more accurate measures across an array of activities beyond steps (e.g., cycling and swimming).…”
Section: Study Limitationsmentioning
confidence: 99%
“…Outcome measures were number of steps and minutes of PA by intensity level using two accelerometers: the Actigraph (Pensacola, FL) GT3X+ (primary measure) and Fitbit One (secondary measure). The Actigraph GT3X+ is a valid and reliable measure of PA among adults 46,47 and thus provided primary measures of PA change from the baseline week to Week 6. The Fitbit One's technology allowed collection of additional days of PA measurement throughout the entire study period (up to 49 days).…”
Section: Introductionmentioning
confidence: 99%
“…The StepWatch 3 activity monitor was selected to measure participants' activity over the duration of the study. The StepWatch 3 records the number of steps taken by the wearer in 1 min increments for periods of up to 60 d. The StepWatch 3 has excellent evidence of measurement reliability and validity across patient populations, including persons with limb loss [69][70]. Data from the activity monitor was downloaded to a laptop computer at each assessment, according the manufacturer's instructions.…”
Section: Physical Performance Measuresmentioning
confidence: 99%
“…Accelerometers also have limited intrarater consistency. 19 The prevalence rates of individuals living with type 2 diabetes and obesity continue to increase. The VLM program is a virtual lifestyle change program based on the DPP protocols and curriculum offering a novel approach to extend behavioral counseling beyond the usual clinical setting.…”
Section: Sherifali Et Almentioning
confidence: 99%